September 27, 2025
Montelukast Neuropsychiatric Effects, Levothyroxine and Orlistat Interaction,
Montelukast Neuropsychiatric Effects, Levothyroxine and Orlistat Interaction,
EPVC, Newsletter, Tirzepatide, Gastroparesis, Glyceryl Trinitrate, Nitroglycerin
Afatinib, Lenvatinib, Lenvima, Kisplyx
Major global health organizations, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), do not recognize autism as a known adverse drug reaction (ADR) of paracetamol. Review of Studies The controversy largely stems from observational studies (not clinical trials) that suggested a potential association between prenatal exposure to paracetamol and a slightly...
The newsletter is structured into three main sections, each containing crucial safety information: 1. Regulatory Matters This section details specific regulatory actions taken by authorities worldwide concerning various medicinal products. 2. Safety of Medicinal Products This section provides important safety reminders and new information on specific drugs. 3. Feature: Key Recommendations from WHO...
The newsletter is structured into three core sections, each highlighting significant safety and regulatory developments. 1. Regulatory Matters This section details specific regulatory actions and safety reviews undertaken by national health authorities. 2. Safety of Medicinal Products This section provides important safety communications and updates on potential risks. 3. Feature: WHO Global Smart...
Advancing Medication Safety Through Knowledge and Vigilance
